

Clare Baecher-Allan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8332783/publications.pdf>

Version: 2024-02-01

35
papers

7,808
citations

279798

23
h-index

526287

27
g-index

38
all docs

38
docs citations

38
times ranked

9037
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple Sclerosis: Mechanisms and Immunotherapy. <i>Neuron</i> , 2018, 97, 742-768.	8.1	610
2	Optimizing human Treg immunotherapy by Treg subset selection and E-selectin ligand expression. <i>Scientific Reports</i> , 2018, 8, 420.	3.3	23
3	Effector T Cells in Multiple Sclerosis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a029025.	6.2	192
4	Dimethyl fumarate downregulates the immune response through the HCA2/GPR109A pathway: Implications for the treatment of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 23, 46-50.	2.0	20
5	Nonapoptotic and Extracellular Activity of Granzyme B Mediates Resistance to Regulatory T Cell (Treg) Suppression by HLA-DR ^{hi} CD25 ^{hi} CD127 ^{lo} Tregs in Multiple Sclerosis and in Response to IL-6. <i>Journal of Immunology</i> , 2015, 194, 2180-2189.	0.8	42
6	Regulation of Gene Expression in Autoimmune Disease Loci and the Genetic Basis of Proliferation in CD4 ⁺ Effector Memory T Cells. <i>PLoS Genetics</i> , 2014, 10, e1004404.	3.5	46
7	The Reduced Suppression of Regulatory T Cells from Patients with Multiple Sclerosis is due to Granzyme B Mediated CD4 T Cell Resistance. <i>Clinical Immunology</i> , 2010, 135, S22.	3.2	0
8	Automated high-dimensional flow cytometric data analysis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 8519-8524.	7.1	355
9	Soluble IL-2RA Levels in Multiple Sclerosis Subjects and the Effect of Soluble IL-2RA on Immune Responses. <i>Journal of Immunology</i> , 2009, 182, 1541-1547.	0.8	136
10	Cutting Edge: Responder T Cells Regulate Human DR ⁺ Effector Regulatory T Cell Activity via Granzyme B. <i>Journal of Immunology</i> , 2009, 183, 4843-4847.	0.8	43
11	The role of the <i>CD58</i> locus in multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 5264-5269.	7.1	185
12	OR.4. Cellular Senescence in Terminally Differentiated Human CD4 ⁺ CD25 ^{hi} IL-7R ^{neg} HLA-DR ⁺ Regulatory T Cells. <i>Clinical Immunology</i> , 2009, 131, S6-S7.	3.2	0
13	OR.55. Transforming Growth Factor-beta is Crucial for the Differentiation and Regulation of Interleukin 9-producing Human CD4 ⁺ T Cells. <i>Clinical Immunology</i> , 2009, 131, S24.	3.2	0
14	IL-17 ⁺ producing human peripheral regulatory T cells retain suppressive function. <i>Blood</i> , 2009, 113, 4240-4249.	1.4	422
15	Multiple Sclerosis and Regulatory T Cells. <i>Journal of Clinical Immunology</i> , 2008, 28, 697-706.	3.8	139
16	OR.39. Differentiation of Natural Human CD4 ⁺ CD25 ^{high} Tregs to Th17 Effector Cells. <i>Clinical Immunology</i> , 2008, 127, S18.	3.2	0
17	SY-23 Human CD4 ⁺ CD25 ^{high} natural Tregs and Th17 effector cells are related. <i>Cytokine</i> , 2008, 43, 305.	3.2	0
18	Response to Comment on "MHC Class II Expression Identifies Functionally Distinct Human Regulatory T Cells". <i>Journal of Immunology</i> , 2008, 180, 3626-3626.	0.8	1

#	ARTICLE	IF	CITATIONS
19	CD4+ CD25+ Regulatory Cells from Human Peripheral Blood Express Very High Levels of CD25 Ex Vivo. Novartis Foundation Symposium, 2008, 252, 67-91.	1.1	75
20	Multiple Sclerosis and Regulatory T Cells. , 2008, , 265-277.		0
21	Human regulatory T cells and their role in autoimmune disease. Immunological Reviews, 2006, 212, 203-216.	6.0	226
22	Immune regulation in tumor-bearing hosts. Current Opinion in Immunology, 2006, 18, 214-219.	5.5	47
23	Human CD25 ^{high} Tregs: Isolation by beads versus by FACS sorting. Clinical Immunology, 2006, 120, 234-235.	3.2	8
24	Regulatory cells and human cancer. Seminars in Cancer Biology, 2006, 16, 98-105.	9.6	74
25	MHC Class II Expression Identifies Functionally Distinct Human Regulatory T Cells. Journal of Immunology, 2006, 176, 4622-4631.	0.8	355
26	The potential for targeting CD4+CD25+ regulatory T cells in the treatment of multiple sclerosis in humans. , 2005, , 133-151.		1
27	Multiple sclerosis. Immunological Reviews, 2005, 204, 208-231.	6.0	267
28	Functional analysis of highly defined, FACS-isolated populations of human regulatory CD4CD25 T cells. Clinical Immunology, 2005, 115, 10-18.	3.2	145
29	Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis. Journal of Experimental Medicine, 2004, 199, 971-979.	8.5	1,608
30	Suppressor T Cells in Human Diseases. Journal of Experimental Medicine, 2004, 200, 273-276.	8.5	155
31	Human CD4+CD25+ regulatory T cells. Seminars in Immunology, 2004, 16, 89-98.	5.6	343
32	Regulatory T cells in type 1 diabetes mellitus. Current Opinion in Endocrinology, Diabetes and Obesity, 2004, 11, 85-90.	0.6	0
33	Isolation and functional characterization of regulatory CD25 ^{bright} CD4 ⁺ T cells from the target organ of patients with rheumatoid arthritis. European Journal of Immunology, 2003, 33, 215-223.	2.9	398
34	Inhibition of Human CD4+CD25+high Regulatory T Cell Function. Journal of Immunology, 2002, 169, 6210-6217.	0.8	237
35	CD4+CD25 ^{high} Regulatory Cells in Human Peripheral Blood. Journal of Immunology, 2001, 167, 1245-1253.	0.8	1,655